China considers mixing vaccines to bolster efficacy - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
新型冠状病毒

China considers mixing vaccines to bolster efficacy

Disease control centre makes first public admission that there are efficacy problems with domestic jabs
00:00

{"text":[[{"start":13.61,"text":"The Chinese Center for Disease Control and Prevention has raised the prospect of mixing vaccines and varying doses to boost efficacy, the first time a government body has acknowledged concerns over the effectiveness of homegrown jabs. "}],[{"start":28.93,"text":"Gao Fu, CDC head, told a conference on Saturday that the agency was “considering how to solve the problem that the efficacy of existing vaccines is not high”, according to local media. "},{"start":40.984,"text":"Gao proposed mixing different vaccines as well as amending the sequence of doses, such as changing the number and quantity of doses, and the interval between them. "}],[{"start":51.739999999999995,"text":"Any new strategy will have ramifications for the more than 20 countries that China said it was supplying in mostly bilateral “vaccine diplomacy” deals. "}],[{"start":61.66,"text":"As of March, China had supplied 40m doses to countries across the globe, including Brazil, Serbia and the United Arab Emirates, prompting the US and its allies to launch their own drive to supply 1bn doses of Johnson & Johnson’s Covid-19 vaccine to south-east Asian nations. "}],[{"start":81.38,"text":"Chile, which has relied on China’s Sinovac vaccine for its inoculation campaign, is in the midst of another Covid-19 wave from new variants. "},{"start":90.984,"text":"The country has administered 62 doses per 100 residents, according to the Financial Times vaccine tracker, the third-highest rate in the world. "}],[{"start":100.88,"text":"A recent study of the effectiveness of Chile’s vaccination programme found the efficacy of a single dose of the Sinovac jab was just 3 per cent, compared with 56 per cent with two shots. "},{"start":113.109,"text":"However, local health experts have not linked the latest wave to the vaccine’s efficacy rate. "}],[{"start":120.19999999999999,"text":"Social-media posts on Gao’s remarks were swiftly censored, according to Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations. "}],[{"start":131.1,"text":"“It is the first time . . . a government official publicly admitted that the protection rate is a concern in the vaccination drive,” Huang added. "},{"start":139.47899999999998,"text":"China had administered 65m doses across the country by the middle of March. "}],[{"start":145.60999999999999,"text":"Unlike other vaccine producers, China’s manufacturers have not published their phase 3 trial data, leading to accusations of a lack of transparency over the vaccine’s effectiveness on different groups. "}],[{"start":158.85999999999999,"text":"For now, the main jabs approved for use in China are the traditional “inactivated virus” vaccines produced by Sinopharm, Sinovac and other domestic groups. "}],[{"start":169.94,"text":"Sinopharm claims a 79 per cent efficacy rate, similar to those achieved by AstraZeneca in its US trials. "},{"start":178.232,"text":"However, while AstraZeneca revised down its rates after facing criticism for releasing incomplete data, neither Sinopharm nor any of its Chinese peers have released phase 3 data for public scrutiny. "}],[{"start":193.07999999999998,"text":"Peter English, a retired communicable disease control consultant at Public Health England, said it was “astonishing” that phase 3 trial data for the Chinese vaccines had not yet been published. "}],[{"start":205.82999999999998,"text":"“We have little information on how effective these vaccines are,” he said, adding efficacy data against variants of concern was needed. "},{"start":214.68399999999997,"text":"Still, English said it was “interesting” that China was considering mixing and matching vaccines after moves from France and Germany to do so following safety concerns about the Oxford/AstraZeneca shot. "}],[{"start":227.89999999999998,"text":"Sinovac Biotech’s CoronaVac vaccine has an overall efficacy rate of 51 per cent among people aged between 18 and 60, according to documents published by a Hong Kong panel of experts. "}],[{"start":241.45999999999998,"text":"However, CoronaVac phase 1 and 2 data published in The Lancet found the shots were “safe and well tolerated”. "}],[{"start":249.89,"text":"Gao also warned that reopening China’s borders to foreigners, who have been barred from entering the country since March last year, posed a risk to elderly people, who have not yet been vaccinated. "}],[{"start":262.69,"text":"The timing of relaxing border restrictions will affect attendees at Beijing’s Winter Olympic Games in February 2022. "}],[{"start":271.6,"text":"Additional reporting by Donato Mancini in Rome "}],[{"start":275.12,"text":""}]],"url":"https://creatives.ftacademy.cn/album/001092107-1618190844.mp3"}

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

停车场破产警示热衷售后回租的零售商

那些将旗下物业售后回租的英国超市,应当从NCP的倒闭中汲取教训。

油价涨到每桶100美元,会加速电动汽车转型吗?

随着燃油价格攀升、前景愈发不确定,汽车选购与制造的经济账已难以忽视。

Lex专栏:铸犁为剑——给欧洲工业吹响的战斗号角

在重整军备的推动下,汽车制造商迎来了革新其生产线的又一次机遇。

为何仍应看多黄金?

库珀:尽管这种贵金属在中东战争期间遭到抛售,但其前景仍更为乐观。

试图摆脱对微软依赖的德国联邦州

在各国领导人日益主张欧洲减少对美国科技巨头的依赖之际,追求“数字主权”的努力使得石勒苏益格-荷尔斯泰因州成为欧洲的一块“试验田”。

FT社评:价格管制重返主流令人不安

价格管制虽然能带来短期纾困,但也会衍生新的问题。与其关注价格管制,各国政府不如把重点放在提高生产率上。
设置字号×
最小
较小
默认
较大
最大
分享×